
Alzamend Neuro (ALZN) Stock Forecast & Price Target
Alzamend Neuro (ALZN) Analyst Ratings
Bulls say
Alzamend Neuro Inc. has demonstrated significant progress in its clinical pipeline for addressing neurodegenerative diseases and psychiatric disorders, particularly with the positive top-line results reported in June 2023. The company's innovative drug candidates, AL001 and AL002, leverage novel therapeutic approaches that could potentially transform treatment options in the Alzheimer's market, indicating strong developmental promise. Additionally, the current valuation of the company remains attractive, suggesting potential upside based on a net present value analysis that reflects the market's recognition of the company's growth potential and upcoming milestones.
Bears say
Alzamend Neuro Inc reported a net loss of $2.7 million, translating to an earnings per share (EPS) of $(1.28), which significantly exceeded estimates of $(0.69). The company operates in the high-risk biopharmaceutical sector, where the development of novel treatments for neurodegenerative diseases faces numerous challenges, including the need for securing regulatory approvals and demonstrating product efficacy in clinical trials. Additionally, potential liquidity and balance sheet risks, coupled with a competitive and changing healthcare landscape, contribute to a negative outlook for the company's financial stability and stock performance.
This aggregate rating is based on analysts' research of Alzamend Neuro and is not a guaranteed prediction by Public.com or investment advice.
Alzamend Neuro (ALZN) Analyst Forecast & Price Prediction
Start investing in Alzamend Neuro (ALZN)
Order type
Buy in
Order amount
Est. shares
0 shares